← All trials
NCT06147622
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 29, 2024
- Primary completion
- Mar 31, 2024
- Completion date
- May 31, 2024
- First posted
- Nov 27, 2023
- Last posted
- Nov 30, 2023
- Enrollment
- 8
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kinnov TherapeuticsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.